Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-05T14:51:48.715Z Has data issue: false hasContentIssue false

21 - Solving Global Mental Health as a Delivery Problem

Toward a Critical Epistemology of the Solution

from Section Four - Psychiatric Practice in Global Context

Published online by Cambridge University Press:  05 July 2015

Laurence J. Kirmayer
Affiliation:
McGill University, Montréal
Robert Lemelson
Affiliation:
University of California, Los Angeles
Constance A. Cummings
Affiliation:
Foundation for Psychocultural Research, California
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Re-Visioning Psychiatry
Cultural Phenomenology, Critical Neuroscience, and Global Mental Health
, pp. 544 - 574
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abas, M., Baingana, F., Broadhead, J., Iacoponi, E., & Vanderpyl, J. (2003). Common mental disorders and primary health care: Current practice in low-income countries. Harvard Review of Psychiatry, 11, 166–73. http://dx.doi.org/10.1080/10673220303954CrossRefGoogle ScholarPubMed
Abraham, J. (2010). Pharmaceuticalization of society in context: Theoretical, empirical and health dimensions. Sociology, 44, 603–22. http://dx.doi.org/10.1177/0038038510369368CrossRefGoogle Scholar
Alexander, G. C., Gallagher, S. A., Mascola, A., Moloney, R. M., & Stafford, R. S. (2011). Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiology and Drug Safety, 20(2), 177–84. http://dx.doi.org/10.1002/pds.2082CrossRefGoogle Scholar
Applbaum, K. (2011). Broadening the marketing concept: Service to humanity, or privatization of the public good? In Zwick, D. & Cayla, J. (Eds.), Inside marketing (pp. 269–98). New York, NY: Oxford University Press. http://dx.doi.org/10.1093/acprof:oso/9780199576746.003.0013Google Scholar
Applbaum, K. (2010). Shadow science: Zyprexa, Eli Lilly and the globalization of pharmaceutical damage control. BioSocieties, 5, 236–55. http://dx.doi.org/10.1057/biosoc.2010.5CrossRefGoogle Scholar
Applbaum, K. (2009a). Is marketing the enemy of pharmaceutical innovation? The Hastings Center Report, 39(4), 1317. http://dx.doi.org/10.1353/hcr.0.0157CrossRefGoogle ScholarPubMed
Applbaum, K. (2009b). Getting to yes: Corporate power and the creation of a psychopharmaceutical blockbuster. Culture, Medicine, and Psychiatry, 33, 185215. http://dx.doi.org/10.1007/s11013-009-9129-3CrossRefGoogle ScholarPubMed
Applbaum, K. (2009c). Consumers are patients! Shared decision making and treatment non-compliance as business opportunity. Transcultural Psychiatry, 46, 107–30. http://dx.doi.org/10.1177/1363461509102290CrossRefGoogle ScholarPubMed
Applbaum, K. (2006). Educating for global mental health: American pharmaceutical companies and the adoption of SSRIs in Japan. In Petryna, A., Lakoff, A., & Kleinman, A. (Eds.), Pharmaceuticals and globalization: Ethics, markets, practices (pp. 85110). Durham, NC: Duke University Press.Google Scholar
Applbaum, K. (2004a). The marketing era: From professional practice to global provisioning. London, England: Routledge.CrossRefGoogle Scholar
Applbaum, K. (2004b). How to organize a psychiatric congress. Anthropological Quarterly, 77, 303–10. http://dx.doi.org/10.1353/anq.2004.0067CrossRefGoogle Scholar
Ban, T.A. (2006). Academic psychiatry and the pharmaceutical industry. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30, 2941. http://dx.doi.org/10.1016/j.pnpbp.2005.11.014CrossRefGoogle ScholarPubMed
Barbui, C., Dua, T., van Ommeren, M., Yasamy, T., Fleischmann, A., Clark, N., … Saxena, S. (2010). Challenges in developing evidence-based recommendations using the GRADE approach: The case of mental, neurological, and substance use disorders. PLOS Medicine, 8, e1000322. http://dx.doi.org/10.1371/journal.pmed.1000322Google Scholar
Baudrillard, J. (1996). The system of objects (J. Benedict, Trans.). London, England: Verso. (Original work published 1968)Google Scholar
Behague, D. P. (2008). The domains of psychiatric practice: From centre to periphery. Culture, Medicine, and Psychiatry, 32, 140–51. http://dx.doi.org/10.1007/s11013-008-9096-0CrossRefGoogle ScholarPubMed
Berrios, G. E., & Marková, I. S. (2015). Toward a new epistemology of psychiatry. In Kirmayer, L. J., Lemelson, R., & Cummings, C. A. (Eds.), Re-visioning psychiatry: Cultural phenomenology, critical neuroscience, and global mental health (pp. 4164). New York, NY: Cambridge University Press.CrossRefGoogle Scholar
Biehl, J. (2007a). A life: Between psychiatric drugs and social abandonment. In Biehl, J., Good, B., & Kleinman, A. (Eds.), Subjectivity: Ethnographic investigations, (pp. 397421). Durham, NC: Duke University Press. http://dx.doi.org/10.1525/california/9780520247925.003.0015CrossRefGoogle Scholar
Biehl, J. (2007b). Pharmaceuticalization: AIDS treatment and global health politics. Anthropological Quarterly, 80, 10831126. http://dx.doi.org/10.1353/anq.2007.0056CrossRefGoogle Scholar
Biehl, J., Good, B., & Kleinman, A. (Eds.). (2007). Subjectivity: Ethnographic investigations. Durham, NC: Duke University Press. http://dx.doi.org/10.1525/california/9780520247925.001.0001CrossRefGoogle Scholar
Biehl, J., & Moran-Thomas, A. (2009). Symptom: Subjectivities, social ills, technologies. Annual Review of Anthropology, 38, 267–88. http://dx.doi.org/10.1146/annurev-anthro-091908-164420CrossRefGoogle Scholar
Buse, K., & Walt, G. (2000). Global private-public partnerships: A new development in health? Bulletin of the World Health Organization, 78(4), 119.Google Scholar
Cohen, A., Kleinman, A., & Saraceno, B. (Eds.). (2002). World mental health casebook: Social and mental health programs in low-income countries. New York, NY: Kluwer Academic. http://dx.doi.org/10.1007/b112400CrossRefGoogle Scholar
Cosgrove, L., & Bursztajn, H. (2010). Undue pharmaceutical influence on psychiatric practice. Psychiatric Times, 27, 16.Google Scholar
Das, V., & Das, R. (2006). Urban health and pharmaceutical consumption in Delhi, India. Journal of Biosocial Science, 38, 6982. http://dx.doi.org/10.1017/S002193200500091XCrossRefGoogle ScholarPubMed
Das, A., & Rao, M. (2012). Universal mental health: Re-evaluating the call for global mental health. Critical Public Health, 22(4), 383–89. http://dx.doi.org/10.1080/09581596.2012.700393CrossRefGoogle Scholar
de Menil, V, Cohen, A. (2009). Rational use and rationale for use: psychiatric medication at an Argentine institution for intellectual disability. Transcultural Psychiatry, 46(4), 651–71. http://dx.doi.org/10.1177/1363461509351377CrossRefGoogle ScholarPubMed
Desjarlais, R., Eisenberg, L., Good, B., & Kleinman, A. (1995). World mental health: Problems and priorities in low-income countries. New York, NY: Oxford University Press.CrossRefGoogle Scholar
Ecks, S. (2009). Unseen drug dissemination: Rethinking the “treatment gap” for antidepressants in India. Paper presented at the Society for Medical Anthropology Conference, Yale University, New Haven, CT.Google Scholar
Ecks, S., & Basu, S. (2009). The unlicensed lives of antidepressants in India: Generic drugs, unqualified practitioners, and floating prescriptions. Transcultural Psychiatry, 46, 86106. http://dx.doi.org/10.1177/1363461509102289CrossRefGoogle ScholarPubMed
Farmer, P. (1999). Infections and inequalities: The modern plagues. Berkeley: University of California Press.Google Scholar
Friedman, R.A. (2012, September 24). A call for caution on antipsychotic drugs. New York Times. Retrieved from http://www.nytimes.com/2012/09/25/health/a-call-for-caution-in-the-use-of-antipsychotic-drugs.htmlGoogle Scholar
Gill, S. S., Rochon, P. A., Herrmann, N., Lee, P. E., Sykora, K. Gunraj, N., … Mamdani, M. (2005). Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective cohort study. BMJ, 330. http://dx.doi.org/10.1136/bmj.38330.470486.8FCrossRefGoogle Scholar
Glick, D., & Applbaum, K. (2010). Dangerous noncompliance: A narrative analysis of a CNN special investigation into mental illness. Anthropology & Medicine, 17, 229–44. http://dx.doi.org/10.1080/13648470.2010.493605CrossRefGoogle ScholarPubMed
Granovetter, M. (1985). Economic action and social structure: The problem of embeddedness. American Journal of Sociology, 91(3), 481510.CrossRefGoogle Scholar
Greene, J. (2011). Making medicines essential: The emergent centrality of pharmaceuticals in global health. BioSocieties, 6(1), 1033. http://dx.doi.org/10.1057/biosoc.2010.39CrossRefGoogle Scholar
Greene, J. (2007). Prescribing by numbers. Baltimore, MD: Johns Hopkins University Press.CrossRefGoogle Scholar
Greene, J. (2004). Therapeutic infidelities: “Noncompliance” enters the medical literature, 1955–1975. Social History of Medicine, 17, 327–43. http://dx.doi.org/10.1093/shm/17.3.327Google Scholar
Harvey, D. (2005). A brief history of neoliberalism. New York, NY: Oxford University Press.CrossRefGoogle Scholar
Healy, D. (n.d.). Enforced compliance: The role of treatment induced stress syndrome. Unpublished manuscript.Google Scholar
Healy, D. (2008). Mania: A short history of a disorder. Baltimore, MD: Johns Hopkins University Press.CrossRefGoogle Scholar
Healy, D. (2006). The latest mania: Selling bipolar disorder. PLOS Medicine, 3(4), e185. http://dx.doi.org/10.1371/journal.pmed.0030185CrossRefGoogle ScholarPubMed
Healy, D. (2004). Let them eat Prozac. New York, NY: New York University Press.Google Scholar
Healy, D. (2002). The creation of psychopharmacology. Cambridge, MA: Harvard University Press.CrossRefGoogle Scholar
Healy, D. (1997). The antidepressant era. Cambridge, MA: Harvard University Press.Google Scholar
Hunt, L. M., & Arar, N.H. (2001). An analytical framework for contrasting patient and provider views of the process of chronic disease management. Medical Anthropology Quarterly, New Series, 15, 347–67.CrossRefGoogle ScholarPubMed
Jain, S. & Jadhav, S. (2009). Pills that swallow policy: Clinical ethnography of a community mental health program in Northern India. Transcultural Psychiatry, 46, 6085. http://dx.doi.org/10.1177/1363461509102287CrossRefGoogle ScholarPubMed
Jenkins, J. H., & Barrett, R. (Eds.). (2004). Schizophrenia, culture, & subjectivity. New York, NY: Cambridge University Press.Google Scholar
Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188, 122–7. http://dx.doi.org/10.1192/bjp.188.2.122CrossRefGoogle ScholarPubMed
Kirmayer, L. J. (2002). Psychopathology in a globalizing world: The use of antidepressants in Japan. Transcultural Psychiatry, 39, 295312. http://dx.doi.org/10.1177/136346150203900302CrossRefGoogle Scholar
Kirmayer, L. J. (2006). Beyond the “New Cross-Cultural Psychiatry”: Cultural biology, discursive psychology and the ironies of globalization. Transcultural Psychiatry, 43, 126–44. http://dx.doi.org/10.1177/1363461506061761CrossRefGoogle ScholarPubMed
Kirmayer, L. J., & Minas, H. (2000). The future of cultural psychiatry: An international perspective. Canadian Journal of Psychiatry, 45, 438–46.CrossRefGoogle ScholarPubMed
Kitanaka, J. (2006). Society in distress: The psychiatric production of depression in contemporary Japan. Doctoral dissertation, Department of Anthropology, McGill University, Montréal, Québec.Google Scholar
Klein, M. (2000). No logo. New York, NY: Picador.Google Scholar
Kleinman, A. (1999). The new bioethics. Daedalus, 128, 6999.Google ScholarPubMed
Koberstein, W. (2002, September 1). When worlds collide: The unleashed power of marketing/R&D collaboration. Pharmaceutical Executive. http://www.pharmexec.com/node/242598?rel=canonicalGoogle Scholar
Lacasse, J. R., and Leo, J. (2005). Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLOS Medicine, 2(12), e392. http://dx.doi.org/10.1371/journal.pmed.0020392CrossRefGoogle ScholarPubMed
Lakoff, A. (2006). Pharmaceutical reason: Knowledge and value in global psychiatry. Cambridge, England: Cambridge University Press.CrossRefGoogle Scholar
Leibing, A. (2009). Tense prescriptions? Alzheimer's medications and the anthropology of uncertainty, Transcultural Psychiatry, 46, 180206. http://dx.doi.org/10.1177/1363461509102297CrossRefGoogle ScholarPubMed
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., … Hsiao, J. K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209–23. http://dx.doi.org/10.1056/NEJMoa051688CrossRefGoogle ScholarPubMed
Luhrmann, T. M. (2007). Social defeat and the culture of chronicity: Or, why schizophrenia does so well over there and so badly here. Culture, Medicine, and Psychiatry, 31, 135–72. http://dx.doi.org/10.1007/s11013-007-9049-zCrossRefGoogle Scholar
Matheson, A. (2008). Corporate science and the husbandry of scientific and medical knowledge by the pharmaceutical industry. BioSocieties, 3, 355–82. http://dx.doi.org/10.1017/S1745855208006297CrossRefGoogle Scholar
Mezzich, J. E., Kirmayer, L. J., Kleinman, A., Fabrega, H. Jr., Parron, D. L., Good, B. J., … Manson, S. M. (1999). The place of culture in DSM-IV. The Journal of Nervous and Mental Disease, 187(8), 457–64. http://dx.doi.org/10.1097/00005053-199908000-00001CrossRefGoogle ScholarPubMed
Panitch, L., & Leys, C. (2010). Morbid symptoms: Health under capitalism. New York, NY: Monthly Review Press.Google Scholar
Patel, V., Boyce, N., Collins, P. Y., Saxena, S., & Horton, R. (2011). A renewed agenda for global mental health. Lancet, 378(9801), 1441–2. http://dx.doi.org/ 10.1016/S0140-6736(11)61385-8CrossRefGoogle ScholarPubMed
Parkar, S. R., Fernandes, J., & Weiss, M. G. (2003). Contextualizing mental health: Gendered experiences in a Mumbai slum. Anthropology & Medicine, 10, 291308. http://dx.doi.org/10.1080/1364847032000133825CrossRefGoogle Scholar
Patel, V., & Thornicroft, G. (2009). Packages of care for mental, neurological and substance abuse disorders in low- and middle-income countries [PLOS series]. PLOS Medicine, 6, 12.Google Scholar
Petryna, A. (2009). When experiments travel: Clinical trials and the global search for human subjects. Princeton, NJ: Princeton University Press.CrossRefGoogle Scholar
Petryna, A., & Kleinman, A. (2006). The pharmaceutical nexus. In Petryna, A., Lakoff, A., & Kleinman, A. (Eds.), Pharmaceuticals and globalization: Ethics, markets, practices (pp. 132). Durham, NC: Duke University Press.Google Scholar
Pinto, S. (2009). Crises of commitment: Ethics of intimacy, kin, and confinement in global psychiatry. Medical Anthropology, 28, 110. http://dx.doi.org/10.1080/01459740802631718CrossRefGoogle ScholarPubMed
Prince, M., Patel, V., Saxena, S., Maj, M., Maselko, J., Phillips, M. R., & Rahman, A. (2007). No health without mental health. The Lancet, 370, 859–77. http://dx.doi.org/10.1016/S0140-6736(07)61238-0CrossRefGoogle ScholarPubMed
Rose, N. (2004). Becoming neurochemical selves. In Stehr, N. (Ed.), Biotechnology, commerce and civil society (pp. 89128). New York, NY: Transaction Press.Google Scholar
Rosenheck, R. A., Leslie, D. L., Sindelar, J. L., Miller, E. A., Tariot, P. N., Dagerman, K. S., … Schneider, L. S. (2007). Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Archives of General Psychiatry, 64, 1259–68. http://dx.doi.org/10.1001/archpsyc.64.11.1259CrossRefGoogle Scholar
Rosenheck, R. (2005). The growth of psychopharmacology in the 1990s: Evidence-based practice or irrational exuberance? International Journal of Law and Psychiatry, 28, 467–83. http://dx.doi.org/10.1016/j.ijlp.2005.08.005CrossRefGoogle ScholarPubMed
Rouse, C. (2010). Patient and practitioner noncompliance: Rationing, therapeutic uncertainty, and the missing conversation. Anthropology & Medicine, 17, 187200. http://dx.doi.org/10.1080/13648470.2010.493602CrossRefGoogle ScholarPubMed
Sismondo, S. (2007). Ghost management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLOS Medicine, 4(9), e286. doi:10.1371/journal.pmed.0040286. http://dx.doi.org/10.1371/journal.pmed.0040286CrossRefGoogle ScholarPubMed
Spielmans, G. (2009). The promotion of olanzapine in primary care: An examination of internal industry documents. Social Science and Medicine, 69, 1420. http://dx.doi.org/10.1016/j.socscimed.2009.05.001CrossRefGoogle ScholarPubMed
Timmermans, K. (2007). Monopolizing clinical trial data: Implications and trends. PLOS Medicine, 4(2), e2. http://dx.doi.org/10.1371/journal.pmed.0040002CrossRefGoogle ScholarPubMed
Tone, A. (2009). The age of anxiety: A history of America's turbulent affair with tranquilizers. New York, NY: Basic Books.Google Scholar
Vargo, S. L., & Lusch, R. F. (2004). Evolving to a new dominant logic for marketing. Journal of Marketing, 68, 117.CrossRefGoogle Scholar
Waitzkin, H., Jasso-Aguilar, R., & Iriart, C. (2007). Privatization of health services in less developed countries: An empirical response to the proposals of the World Bank and Wharton School. International Journal of Health Services, 37(2), 205–27. http://dx.doi.org/10.2190/A1U4-7612-5052-6053CrossRefGoogle Scholar
Whitaker, R. (2005). Anatomy of an epidemic: Psychiatric drugs and the astonishing rise of mental illness in America. Ethical Human Psychology and Psychiatry, 7, 2335.Google Scholar
Whitmarsh, I. (2009). Medical schismogenics: Compliance and “culture” in Caribbean biomedicine. Anthropological Quarterly, 82, 453–82.CrossRefGoogle Scholar
World Health Organization. (2001). World Health Report 2001. Mental health: New understanding, new hope. Retrieved from WHO website: http://www.who.int/whr/2001/en/whr01_en.pdfGoogle Scholar
World Health Organization. (2008). Mental Health Gap Action Programme: Scaling up care for mental, neurological, and substance use disorders. Retrieved from WHO website: http://whqlibdoc.who.int/publications/2008/9789241596206_eng.pdfGoogle Scholar
World Health Organization. (2010). mhGAP Intervention guide for mental, neurological and substance use disorders in non-specialized health settings. Retrieved from WHO website: www.who.int/mental_health/mhgap/en/Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×